|
2026 Journal Article Engineered protein corona by bispecific antibody endows liposome with enhanced tumor targeting ability and mitigated accelerated blood clearance effectWei, Xiaoli, Ding, Tianhao, Xi, Meili, Thurecht, Kristofer J., Howard, Christopher B., Cui, Jiwei, Zhan, Changyou and Zhang, Zui (2026). Engineered protein corona by bispecific antibody endows liposome with enhanced tumor targeting ability and mitigated accelerated blood clearance effect. Nano Today, 66 102923, 102923. doi: 10.1016/j.nantod.2025.102923 |
|
2025 Journal Article Pre-targeting of PEG-based nanomedicines: precise delivery of potent payloadsFletcher, Nicholas, Thurecht, Kristofer, Chu, Weijing, Huda, Pie, Humphries, James and Wood, James (2025). Pre-targeting of PEG-based nanomedicines: precise delivery of potent payloads. Nuclear Medicine and Biology, 150-151 109150, 109150. doi: 10.1016/j.nucmedbio.2025.109150 |
|
2025 Journal Article Development of Thiosemicarbazonato Technetium-99m Complexes for SPECT ImagingMaclean, Rachel, Fletcher, Nicholas, Alsadig, Ahmed, Chu, Weijing, Sihver, Wiebke, Baraban, Larysa, Thurecht, Kristofer, Kubeil, Manja, Tuck, Kellie and Paterson, Brett (2025). Development of Thiosemicarbazonato Technetium-99m Complexes for SPECT Imaging. Nuclear Medicine and Biology, 150-151 109249, 109249. doi: 10.1016/j.nucmedbio.2025.109249 |
|
2025 Journal Article The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicineForgham, Helen, Chang, Yixin, Wang, Yao, Zhu, Jiayuan, Liu, Liwei, Biggs, Heather, Kakinen, Aleksandr, Jiang, Yuhao, You, Xinru, Thurecht, Kristofer J., Ma, Shaohua, Ju, Lining Arnold, Tao, Wei, Davis, Thomas P., Wong, Joyce Y. and Qiao, Ruirui (2025). The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicine. Science Advances, 11 (43) eadx1576, eadx1576. doi: 10.1126/sciadv.adx1576 |
|
2025 Conference Publication The glycogen synthase kinase-3β inhibitor 9-ING-41 in combination with chemoimmunotherapy provides long-term survival in the Th-MYCN mouse modelMurray, Jayne, Somers, Klaartje, Mak, Crystal, Alfred, Stephanie, Brand, Jennifer, Poon, Evon, Fletcher, Nicholas, Li, Pei, Thurecht, Kristofer, Gray, Juliet, Pearson, Andrew Dj., Chesler, Louis, Hogarty, Michael D., Giles, Francis, Fletcher, Jamie, Ziegler, David S., Norris, Murray D. and Haber, Michelle (2025). The glycogen synthase kinase-3β inhibitor 9-ING-41 in combination with chemoimmunotherapy provides long-term survival in the Th-MYCN mouse model. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. doi: 10.1158/1535-7163.TARG-25-B079 |
|
2025 Journal Article Preclinical Evaluation of [<sup>212</sup>Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen–Targeted α-Therapy for Prostate CancerLiu, Feifei, Monterosso, Melissa E., Boucher, Didier, Shakti, Stelle, Li, Kwong Ching, Kim, Chanwoo, Prior, Amber, Sydes, Abby, Soderholm, Amelia T., Fletcher, Nicholas, Akhter, Dewan, Thurecht, Kristofer, Tieu, William, Kuan, Kevin, Horsfall, Aimee, Kumar, Saawan, Koehbach, Johannes, Hammond, Edward, Karmann, Anna, Rose, Stephen, Li, Gary, Puttick, Simon and Kryza, Thomas (2025). Preclinical Evaluation of [212Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen–Targeted α-Therapy for Prostate Cancer. Journal of Nuclear Medicine, 66 (11), jnumed.125.269707-1713. doi: 10.2967/jnumed.125.269707 |
|
2025 Journal Article Development of a novel engineered antibody format for PSMA-targeted radionuclide therapyFletcher, Nicholas L., Houston, Zachary H., Chandler, Peter G., Yan, Eddie, Holgate, Rob, Wheatcroft, Michael and Thurecht, Kristofer J. (2025). Development of a novel engineered antibody format for PSMA-targeted radionuclide therapy. Molecular Pharmaceutics, 22 (7), 3666-3678. doi: 10.1021/acs.molpharmaceut.4c01193 |
|
2025 Conference Publication Retrofitting a cyclotron solid target processing system for radiometal production at AIBN, cyclotron and radiochemistry capabilityStimson, Damion, Barkhausen, Christoph, Najdovski, Ljubco, Gulza, Arif, Dixon, Carl, Maillet, Donald and Thurecht, Kristofer (2025). Retrofitting a cyclotron solid target processing system for radiometal production at AIBN, cyclotron and radiochemistry capability. ANZSNM ASM 2025, Melbourne, VIC, Australia, 23–25 May 2025. Hoboken, NJ, United States: Wiley. doi: 10.1111/imj.70120 |
|
2025 Journal Article Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell-surface markersDietmair, Bettina, Humphries, James, Mercer, Timothy R., Thurecht, Kristofer J., Howard, Christopher B. and Cheetham, Seth W. (2025). Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell-surface markers. Molecular Therapy Nucleic Acids, 36 (2) 102520, 1-7. doi: 10.1016/j.omtn.2025.102520 |
|
2025 Journal Article Immune-modulating nanomedicines for enhanced drug delivery to non-small-cell lung cancerLiu, Feifei, Howard, Christopher B., Huda, Pie, Fletcher, Nicholas L., Bell, Craig A., Blakey, Idriss, Agrez, Michael and Thurecht, Kristofer J. (2025). Immune-modulating nanomedicines for enhanced drug delivery to non-small-cell lung cancer. Biomaterials, 317 123089, 1-14. doi: 10.1016/j.biomaterials.2025.123089 |
|
2025 Journal Article Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancersGough, Madeline, Kwah, Kayden KX., Khan, Tashbib, Ghosh, Saikat, Sun, Biao, Lee, Catherine YJ., Sokolowski, Kamil A., Tse, Brian WC., Wickramasuriya, Lashith, Ferguson, Kaltin, Rogers, Rebecca, Goh, Justin B., Fletcher, Nicholas L., Houston, Zachary H., Thurecht, Kristofer J., Bray, Laura J., Liu, Cheng, Pyke, Christopher, Lim, Elgene, Snell, Cameron E., He, Yaowu, Hooper, John D. and Kryza, Thomas (2025). Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers. Clinical Cancer Research, 31 (8), 1504-1519. doi: 10.1158/1078-0432.ccr-24-2865 |
|
2025 Journal Article Harnessing nanoparticles and bioorthogonal chemistries for improving precision of nuclear medicineEdiriweera, Gayathri R., Li, Mengdie, Fletcher, Nicholas L., Houston, Zachary H., Ahamed, Muneer, Blakey, Idriss and Thurecht, Kristofer J. (2025). Harnessing nanoparticles and bioorthogonal chemistries for improving precision of nuclear medicine. Biomaterials Science, 13 (9), 2297-2319. doi: 10.1039/d4bm01387e |
|
2025 Book Chapter Multifunctional biocompatible hyperbranched polymers as molecular imaging agents and theranosticsBoase, Nathan R. B., Bell, Craig A., Fletcher, Nicholas L. and Thurecht, Kristofer J. (2025). Multifunctional biocompatible hyperbranched polymers as molecular imaging agents and theranostics. Biomedical nanotechnology. (pp. 69-106) edited by Cassandra Callmann. New York, NY USA: Humana New York. doi: 10.1007/978-1-0716-4402-7_5 |
|
2025 Journal Article Lipid nanoparticles and transcranial focused ultrasound enhance the delivery of SOD1 antisense oligonucleotides to the murine brain for ALS therapyEdiriweera, Gayathri R., Sivaram, Amal J., Cowin, Gary, Brown, Mikayla L., McAlary, Luke, Lum, Jeremy S., Fletcher, Nicholas L., Robinson, Liam, Simpson, Joshua D., Chen, Liyu, Wasielewska, Joanna M., Byrne, Ella, Finnie, John W., Manavis, Jim, White, Anthony R., Yerbury, Justin J., Thurecht, Kristofer J. and Vine, Kara L. (2025). Lipid nanoparticles and transcranial focused ultrasound enhance the delivery of SOD1 antisense oligonucleotides to the murine brain for ALS therapy. Journal of Controlled Release, 378, 221-235. doi: 10.1016/j.jconrel.2024.11.074 |
|
2025 Journal Article Nanobody-mediated cellular uptake maximizes the potency of polylysine dendrimers while preserving solid tumor penetrationYuen, Daniel, Feeney, Orlagh M., Noi, Leo, Shengule, Sudhir, McLeod, Victoria M., Reitano, Pauline, Tsegay, Sammi, Hufton, Richard, Houston, Zachary H., Fletcher, Nicholas L., Humphries, James, Thurecht, Kristofer J., Cullinane, Carleen, Owen, David J., Porter, Christopher J.H. and Johnston, Angus P.R. (2025). Nanobody-mediated cellular uptake maximizes the potency of polylysine dendrimers while preserving solid tumor penetration. ACS Nano, 19 (6), 6044-6057. doi: 10.1021/acsnano.4c10851 |
|
2025 Journal Article Multiplexing label-free polymeric nanocarriers via antipolymer antibodiesHumphries, James, Hobson-Peters, Jody, Ghosh, Saikat, Howard, Christopher B., Huda, Pie, Bell, Craig A., Fletcher, Nicholas L., Kempe, Kristian and Thurecht, Kristofer J. (2025). Multiplexing label-free polymeric nanocarriers via antipolymer antibodies. ACS Sensors, 10 (2), 1280-1288. doi: 10.1021/acssensors.4c03184 |
|
2024 Journal Article A novel immunomodulating peptide with potential to complement oligodeoxynucleotide-mediated adjuvanticity in vaccination strategiesAgrez, Michael, Chandler, Christopher, Thurecht, Kristofer J., Fletcher, Nicholas L., Liu, Feifei, Subramaniam, Gayathri, Howard, Christopher B., Parker, Stephen, Turner, Darryl, Rzepecka, Justyna, Knox, Gavin, Nika, Anastasia, Hall, Andrew M., Gooding, Hayley and Gallagher, Laura (2024). A novel immunomodulating peptide with potential to complement oligodeoxynucleotide-mediated adjuvanticity in vaccination strategies. Scientific Reports, 14 (1) 26737, 1-17. doi: 10.1038/s41598-024-78150-7 |
|
2024 Journal Article Patient-specific nanoparticle targeting in human leukemia bloodJu, Yi, Li, Shiyao, Tan, Abigail Er Qi, Pilkington, Emily H., Brannon, Paul T., Plebanski, Magdalena, Cui, Jiwei, Caruso, Frank, Thurecht, Kristofer J., Tam, Constantine and Kent, Stephen J. (2024). Patient-specific nanoparticle targeting in human leukemia blood. ACS Nano, 18 (42), 29021-29035. doi: 10.1021/acsnano.4c09919 |
|
2024 Journal Article Material trends and clinical costings in systematically identified CDER‐approved nanomedicinesJarrett, Thomas Ryan, Pregelj, Lisette, Bell, Craig Andrew, Fletcher, Nicholas Lyle and Thurecht, Kristofer James (2024). Material trends and clinical costings in systematically identified CDER‐approved nanomedicines. Advanced Therapeutics, 7 (10) 2400124. doi: 10.1002/adtp.202400124 |
|
2024 Journal Article A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elementsWood, James Liam, Ghosh, Saikat, Houston, Zachary, Fletcher, Nicholas, Humphries, James, Mardon, Karine, Akhter, Dewan T., Tieu, William, Ivashkevich, Alesia, Wheatcroft, Michael P., Thurecht, Kristofer J. and Codd, Rachel (2024). A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements. Chemical Science, 15 (30), 11748-11760. doi: 10.1039/d4sc02851a |
